Haemophilus influenzae type b conjugate vaccine use and effectiveness

Shaun K. Morris, William J Moss, Neal A Halsey

Research output: Contribution to journalArticle

Abstract

Haemophilus influenzae type b (Hib) is an important cause of invasive bacterial disease in children, including meningitis and pneumonia. The introduction of Hib conjugate vaccines into routine vaccination schedules has contributed to a substantial reduction in the burden of Hib-related disease in many developed countries. However, introduction of Hib conjugate vaccines in developing countries has progressed more slowly. We review the worldwide use and effectiveness of Hib conjugate vaccines. At present, 119 countries have programmes for routine Hib immunisation. WHO estimates that in the developed world 92% of the eligible population is vaccinated against Hib; however, average coverage is 42% in developing countries and only 8% in the poorest countries. Africa and southeast Asia have the lowest rates of Hib vaccine introduction. Vaccine costs and debate about the burden of disease are obstacles to the global use of Hib conjugate vaccine. Even with new funding support, there are many ongoing challenges and vaccine use remains suboptimal, particularly in developing countries.

Original languageEnglish (US)
Pages (from-to)435-443
Number of pages9
JournalLancet Infectious Diseases
Volume8
Issue number7
DOIs
StatePublished - Jul 2008

Fingerprint

Haemophilus influenzae type b
Conjugate Vaccines
Developing Countries
Haemophilus Vaccines
Vaccines
Southeastern Asia
Meningitis
Developed Countries
Immunization
Pneumonia
Appointments and Schedules
Vaccination
Costs and Cost Analysis

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Haemophilus influenzae type b conjugate vaccine use and effectiveness. / Morris, Shaun K.; Moss, William J; Halsey, Neal A.

In: Lancet Infectious Diseases, Vol. 8, No. 7, 07.2008, p. 435-443.

Research output: Contribution to journalArticle

@article{53514cde901a429d91e120a544bea20b,
title = "Haemophilus influenzae type b conjugate vaccine use and effectiveness",
abstract = "Haemophilus influenzae type b (Hib) is an important cause of invasive bacterial disease in children, including meningitis and pneumonia. The introduction of Hib conjugate vaccines into routine vaccination schedules has contributed to a substantial reduction in the burden of Hib-related disease in many developed countries. However, introduction of Hib conjugate vaccines in developing countries has progressed more slowly. We review the worldwide use and effectiveness of Hib conjugate vaccines. At present, 119 countries have programmes for routine Hib immunisation. WHO estimates that in the developed world 92{\%} of the eligible population is vaccinated against Hib; however, average coverage is 42{\%} in developing countries and only 8{\%} in the poorest countries. Africa and southeast Asia have the lowest rates of Hib vaccine introduction. Vaccine costs and debate about the burden of disease are obstacles to the global use of Hib conjugate vaccine. Even with new funding support, there are many ongoing challenges and vaccine use remains suboptimal, particularly in developing countries.",
author = "Morris, {Shaun K.} and Moss, {William J} and Halsey, {Neal A}",
year = "2008",
month = "7",
doi = "10.1016/S1473-3099(08)70152-X",
language = "English (US)",
volume = "8",
pages = "435--443",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",
number = "7",

}

TY - JOUR

T1 - Haemophilus influenzae type b conjugate vaccine use and effectiveness

AU - Morris, Shaun K.

AU - Moss, William J

AU - Halsey, Neal A

PY - 2008/7

Y1 - 2008/7

N2 - Haemophilus influenzae type b (Hib) is an important cause of invasive bacterial disease in children, including meningitis and pneumonia. The introduction of Hib conjugate vaccines into routine vaccination schedules has contributed to a substantial reduction in the burden of Hib-related disease in many developed countries. However, introduction of Hib conjugate vaccines in developing countries has progressed more slowly. We review the worldwide use and effectiveness of Hib conjugate vaccines. At present, 119 countries have programmes for routine Hib immunisation. WHO estimates that in the developed world 92% of the eligible population is vaccinated against Hib; however, average coverage is 42% in developing countries and only 8% in the poorest countries. Africa and southeast Asia have the lowest rates of Hib vaccine introduction. Vaccine costs and debate about the burden of disease are obstacles to the global use of Hib conjugate vaccine. Even with new funding support, there are many ongoing challenges and vaccine use remains suboptimal, particularly in developing countries.

AB - Haemophilus influenzae type b (Hib) is an important cause of invasive bacterial disease in children, including meningitis and pneumonia. The introduction of Hib conjugate vaccines into routine vaccination schedules has contributed to a substantial reduction in the burden of Hib-related disease in many developed countries. However, introduction of Hib conjugate vaccines in developing countries has progressed more slowly. We review the worldwide use and effectiveness of Hib conjugate vaccines. At present, 119 countries have programmes for routine Hib immunisation. WHO estimates that in the developed world 92% of the eligible population is vaccinated against Hib; however, average coverage is 42% in developing countries and only 8% in the poorest countries. Africa and southeast Asia have the lowest rates of Hib vaccine introduction. Vaccine costs and debate about the burden of disease are obstacles to the global use of Hib conjugate vaccine. Even with new funding support, there are many ongoing challenges and vaccine use remains suboptimal, particularly in developing countries.

UR - http://www.scopus.com/inward/record.url?scp=45449119665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45449119665&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(08)70152-X

DO - 10.1016/S1473-3099(08)70152-X

M3 - Article

C2 - 18582836

AN - SCOPUS:45449119665

VL - 8

SP - 435

EP - 443

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

IS - 7

ER -